A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

To join this study, you need to be an adult, aged 18 or older. You should have multiple myeloma that has come back or isn't responding to previous treatments. Importantly, you must either be about to start taking isatuximab as part of your regular medical care, or have already started it within the last three months, based on your doctor’s decision and not because of the study itself.

There are also some reasons why you might not be able to join. For example, you can't be in the study if you're taking isatuximab for a different health problem or if you've recently taken another experimental drug. You also can't participate if you have any health conditions that would make taking isatuximab unsafe for you, as listed in the medicine's official information.

If you join this study, your involvement will last for about two and a half years (2.5 years). You won't be asked to change your current treatment plan with isatuximab; doctors will simply observe your progress as you receive your standard care. This means your appointments and medication schedule will be as agreed with your own doctor.

During this time, you will be asked to complete some questionnaires about your health and how you're feeling, including questions about your quality of life. Doctors will also collect information about your general health, your multiple myeloma, and any other health conditions you might have. They will also record any side effects you experience while taking isatuximab. These activities will generally happen during your regular clinic visits.